If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-30. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
By using "high-expresser" GFP, transgenic rats display high expression in most tissues, and many cells that have not been characterized or have been only poorly characterized in previous GFP-transgenic rats. GFP has been shown to be useful in cryobiology as a viability assay. Correlation of viability as measured by trypan blue assays were 0.97. Another application is the use of GFP co-transfection as internal control for transfection efficiency in mammalian cells. A novel possible use of GFP includes using it as a sensitive monitor of intracellular processes via an eGFP laser system made out of a human embryonic kidney cell line. The first engineered living laser is made by an eGFP expressing cell inside a reflective optical cavity and hitting it with pulses of blue light. At a certain pulse threshold, the eGFP's optical output becomes brighter and completely uniform in color of pure green with a wavelength of 516 nm. Before being emitted as laser light, the light bounces back and forth within the resonator cavity and passes the cell numerous times. By studying the changes in optical activity, researchers may better understand cellular processes. GFP is used widely in cancer research to label and track cancer cells. GFP-labelled cancer cells have been used to model metastasis, the process by which cancer cells spread to distant organs.
=== Harris's loss === Harris's loss to Trump received substantial media analysis in the aftermath of the election. Proposed explanations for the outcome of the race included inflation, the immigration crisis, a global incumbency backlash, Biden's late exit from the race, and the lack of an open Democratic primary process. Democrats and others argued about what went wrong and how the party should move forward.
== Weapons and equipment == According to the United States Department of Defense, China is developing kinetic-energy weapons, high-powered lasers, high-powered microwave weapons, particle-beam weapons, and electromagnetic pulse weapons with its increase of military fundings. Responding to reports that its modernisation is dependent on sales of advanced technology from American allies, PLA senior leadership have stated: "Some have politicized China's normal commercial cooperation with foreign countries, damaging our reputation." These contributions include advanced European diesel engines for Chinese warships, military helicopter designs from Eurocopter, French anti-submarine sonars and helicopters, Australian technology for the Houbei class missile boat, and Israeli supplied American missile, laser and aircraft technology. According to the Stockholm International Peace Research Institute's data, China became the world's third largest exporter of major arms in 2010–14, an increase of 143 percent from the period 2005–2009. SIPRI also calculated that China surpassed Russia to become the world's second largest arms exporter by 2020. China's share of global arms exports hence increased from 3 to 5 percent. China supplied major arms to 35 states in 2010–14. A significant percentage (just over 68 percent) of Chinese exports went to three countries: Pakistan, Bangladesh and Myanmar. China also exported major arms to 18 African states.
Yin vacuity (also termed "vacuity-heat"): heat sensations, possible sweating at night, insomnia, dry pharynx, dry mouth, dark urine, and a "fine" and rapid pulse. Yang vacuity ("vacuity-cold"): aversion to cold, cold limbs, bright white complexion, long voidings of clear urine, diarrhea, pale and enlarged tongue, and a slightly weak, slow and fine pulse. TCM also identifies drugs believed to treat these specific symptom combinations, i.e., to reinforce yin and yang.
The emperors Leo III (r. 717–741) and Constantine V (r. 741–775) were effective leaders, both in government and warfare. They withstood continued Arab attacks, as well as civil war and natural disasters. Constantine's success reestablished the state as a major regional power. Leo's reign produced the Ekloge ton nomon, a code of law that evolved that of Justinian I. He also continued to reform the theme system in order to lead offensive campaigns against the Muslims, culminating in a notable victory in 740. Constantine overcame an early civil war against his brother-in-law Artabasdos, created stability against the new Abbasid Caliphate, campaigned successfully against the Bulgars, and continued to make administrative and military reforms. Both emperors supported iconoclast policies opposing the veneration of religious images, which had them later vilified by biased authors, creating issues that continue to impact modern scholarship; Constantine's reign also saw the loss of Ravenna to the Lombards, and the beginning of a split from the Roman papacy. In 780, Empress Irene assumed power as regent for her son Constantine VI. Although she was a capable administrator who restored the veneration of icons, the empire was destabilised by her conflict with her son. The Bulgars and Abbasids inflicted numerous defeats on the Byzantine armies, and the papacy crowned Charlemagne as Roman emperor in 800. In 802, the unpopular Irene was overthrown by Nikephoros I; he reformed the empire's administration but died in battle against the Bulgars in 811.
Sources: en.wikipedia.org
"Alzheimer's Disease Research Timeline – Alzforum". www.alzforum.org. "Alzheimer's Disease Brain Cell Atlas- brain-map.org". portal.brain-map.org. "What's the deal with Alzheimer's disease and amyloid?". For decades, scientists have concentrated on what now looks to be a blind alley. The Amyloid Mafia. Jonathan M. Gitlin, Ars Technica, Apr 15, 2026
=== Pharmacokinetics === Gepotidacin is rapidly absorbed orally, reaching peak plasma concentrations (tmax) after approximately 2.0 hours. In adults with uncomplicated urinary tract infections (uUTI) and normal renal function, the mean steady-state maximum concentration (Cmax) is 4.2 mcg/mL, and the area under the concentration-time curve over 12 hours AUC(0-12) is 22.8 mcg*hour/mL following a 1500 mg dose every 12 hours. Systemic exposure (Cmax and AUC) increases proportionally with dose. Accumulation of approximately 40% occurs and achieves a steady state by day 3. The absolute bioavailability is about 45%, and standard and moderate fat meals did not significantly affect its absorption. Gepotidacin's pharmacokinetics were found to be generally consistent across different ages, sexes, races, and body weights during modeling and simulation. Gepotidacin has a mean steady-state volume of distribution (Vss) of 172.9 liters and is 25-41% bound to plasma proteins. It has a terminal elimination half-life of approximately 9.3 hours and a total clearance of 33.4 L/hour. The primary metabolic pathway involves CYP3A4, with a minor metabolite (M4, ~11% of circulating drug). The co-administration of other drugs can influence gepotidacin levels. Strong inhibitors of CYP3A4 can increase gepotidacin exposure, whereas strong inducers of CYP3A4 can decrease it. Additionally, gepotidacin, at high concentrations, has shown the potential to increase the exposure of certain other drugs, including digoxin and midazolam.
Mahathir bin Mohamad (Jawi: محاضر بن محمد; Malay: [mahade(r) muhammad, -ðe(r)] ; born 10 July 1925) is a Malaysian politician, physician and author who served as the fourth and seventh prime minister of Malaysia from 1981 to 2003 and again from 2018 to 2020. He was the country's longest-serving prime minister, serving for a cumulative total of 24 years. His political career has spanned more than 75 years, from joining protests opposing citizenship policies for non-Malays in the Malayan Union in the 1940s to forming the Gerakan Tanah Air coalition in 2022. During his premiership, Mahathir was granted the title "Father of Modernisation" (Malay: Bapa Pemodenan) for his pivotal role in transforming the country's economy and infrastructure. At 101 years old, he is the second-oldest living former state leader in the world and the first Malaysian prime minister to reach that age. Born and raised in Alor Setar, Kedah, Mahathir excelled at school and became a physician. He became active in UMNO before entering the parliament of Malaysia in 1964 as the Member of Parliament for Kota Setar Selatan, serving until he lost his seat in 1969, subsequently falling out with Prime Minister Tunku Abdul Rahman and being expelled from UMNO. In 1970, he released the book The Malay Dilemma. When Tunku resigned, Mahathir re-entered UMNO and parliament through Kubang Pasu constituency, and was promoted to Minister of Education from 1974 to 1978 and Minister of Trade and Industry from 1978 to 1981. He became deputy prime minister in 1976 before being sworn in as prime minister in 1981.
However the amino acid tree seems to be more likely since it appears to be free from the synonymous codon-family bias affecting the nucleotide one. Most of the inferences based on amino acids sequences support a clade which includes Branchiopoda, Remipedia, Copepoda and Hexapoda (group A). Using the best amino acids substitution model, CATGTR, also Cephalocarida falls inside this group. In all the analyses group A (with or without Cephalocarida) is sister-group of a clade composed by Malacostraca, Oligostraca and Thecostraca (group B). The following diagram shows the tree resulting from the Dayhoff recoding.
Sources: en.wikipedia.org
While agreeing with the editorial's conclusion, a reply noted that its finding in the negative was guaranteed, given that "global dose estimates or results of mathematical modelling are too inaccurate to be used as dose values for an individual veteran", and that, as of April 2001, no practical method of measuring the expected small doses that each individual veteran would receive had been suggested. The author of the reply, a radiation scientist, went on to suggest a method that had been used several times before, including after the 1986 Chernobyl accident. Despite the widespread use of DU in the Iraq War, at least a year after the conflict began, testing of UK troops was still only in the discussion phase. The Royal Society Working Group on the Health Hazards of Depleted Uranium Munitions (RSDUWG) concluded in 2002 that there were "very low" health risks associated with the use of depleted uranium, though it also ventured that, "[i]n extreme conditions and under worst-case assumptions" lung and kidney damage could occur, and that in "worst-case scenarios high local levels of uranium could occur in food or water that could have adverse effects on the kidney". In 2003, the Royal Society issued another urgent call to investigate the actual health and environmental impact of depleted uranium. The same year, a cohort study of Gulf War veterans found no elevated risks of cancer generally, nor of any specific cancers in particular, though recommended follow up studies.
== Combination drugs == Some DPP-4 inhibitor drugs have received approval from the FDA to be used with metformin concomitantly with additive effect to increase the level of glucagon-like peptide 1 (GLP-1) which also decreases hepatic glucose production.
Metabolism and biosynthesis of serotonin. Pyridoxal phosphate is a cofactor of aromatic L-amino acids decarboxylase. This allows for conversion of 5-hydroxytryptophan (5-HTP) into serotonin (5-HT). This reaction takes place in serotonergic neurons. Metabolism and biosynthesis of histamine. Pyridoxal phosphate is a cofactor of L-histidine decarboxylase. This allows for conversion of histidine into histamine. This reaction takes place in Golgi apparatus in mast cells and in basophils. Next, histamine is stored in granularity in mast cells as a complex with acid residues of heparin proteoglycan while in basophils as a complex with chondroitine sulfate. Metabolism and biosynthesis of GABA (γ-aminobutyric acid). Pyridoxal phosphate is a cofactor of glutamic acid decarboxylase (GAD). This allows for conversion of glutamate into GABA. Reaction takes place in cytoplasm of termination of GABA-ergic neurons, therefore vitamin B6 deficiency may cause epileptic seizures in children. Pyridoxal phosphate also participates in the oxidative deamination of GABA, where it is a cofactor of GABA aminotransferase. Metabolism of ornithine. Pyridoxal phosphate is a cofactor of ornithine decarboxylase. It is therefore associated with the synthesis of polyamines; crucial compounds associated with cell growth and proliferation. Transamination. Pyridoxal phosphate takes part in decomposition and synthesis of amino acids, fats, and carbohydrates, and in the biosynthesis of hormones, neurotransmitters, and heme.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.